---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-24-000169"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:43.931100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025

## Summary
- Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.
- Cash and investments of $406.0M as of Sept 30, 2024; no revenue reported.
- BEACON-IPF Phase 2b/3 trial enrolling well; full enrollment expected Q1 2025, data mid-2026.
- Phase 1 trial of PLN-101095 in solid tumors dosing third cohort; preliminary data early 2025.
- Gary Palmer appointed SVP of Medical Affairs; brings 25+ years from Bristol Myers Squibb.

## SEC filing metadata
- accession: 0001746473-24-000169
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/0001746473-24-000169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/plrx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-24-000169
- JSON: https://secwatch.observer/filing/0001746473-24-000169.json
- Plain text: https://secwatch.observer/filing/0001746473-24-000169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.